國立虎尾科技大學 |

Reactive Oxygen Species = Network Pharmacology and Therapeutic Applications /

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	Reactive Oxygen Species / edited by Harald H. H. W. Schmidt, Pietro Ghezzi, Antonio Cuadrado.
其他題名:	Network Pharmacology and Therapeutic Applications /
其他作者:	Schmidt, Harald H. H. W.
面頁冊數:	VIII, 425 p. 70 illus. in color.online resource. :
Contained By:	Springer Nature eBook
標題:	Pharmacology. -
電子資源:	https://doi.org/10.1007/978-3-030-68510-2
ISBN:	9783030685102

Reactive Oxygen Species = Network Pharmacology and Therapeutic Applications /
Reactive Oxygen Species Network Pharmacology and Therapeutic Applications /[electronic resource] :edited by Harald H. H. W. Schmidt, Pietro Ghezzi, Antonio Cuadrado. - 1st ed. 2021. - VIII, 425 p. 70 illus. in color.online resource. - Handbook of Experimental Pharmacology,2641865-0325 ;. - Handbook of Experimental Pharmacology,224.

Part I: ROS Revisited: Changing the Focus from Oxidative Stress and Redox Biology to Redox Medicine -- Demystifying oxidative stress -- Oxidants in Physiological Processes -- Network Medicine-Based Unbiased Disease Modules for Drug and Diagnostic Target Identification in ROSopathies -- Part II Targeting antioxidant responses -- Development of Telintra as an Inhibitor of Glutathione S-Transferase P -- Perspectives on the Clinical Development of NRF2-Targeting Drugs -- Part III: Inhibiting ROS formation and toxification -- NOX Inhibitors: From Bench to Naxibs to Bedside -- Nitric Oxide Synthase Inhibitors into the Clinic at Last -- Xanthine Oxidoreductase Inhibitors -- Monoamine Oxidase Inhibitors: From Classic to New Clinical Approaches -- Inhibition of Myeloperoxidase -- Part IV: Stimulating/substituting ROS -- Effects of Mammalian Thioredoxin Reductase Inhibitors -- Cardiovascular Therapeutic Potential of the Redox Siblings, Nitric Oxide (NO•) and Nitroxyl (HNO), in the Setting of Reactive Oxygen Species Dysregulation -- Tetrahydrobiopterin and Nitric Oxide Synthase Recouplers -- Part V: Repairing ROS damage -- Soluble Guanylate Cyclase Stimulators and Activators – Peter Sander -- Inhibitors of Advanced Glycation End Product (AGE) Formation and Accumulation.

Reactive oxygen species (ROS) have been implicated in almost every human disease phenotype, without much, if any, therapeutic consequence foremost exemplified by the failure of the so-called anti-oxidants. This book is a game changer for the field and many clinical areas such as cardiology and neurology. The term ‘oxidative stress’ is abandoned and replaced with a systems medicine and network pharmacology-based mechanistic approach to disease. The ROS-related drugs discussed here target either ROS- forming or ROS -modifying enzymes for which there is strong clinical evidence. In addition, ROS targets are included as they jointly participate in causal mechanisms of disease. This approach is transforming the ROS field and represents a breakthrough in redox medicine indicating a path to patient benefit. In the coming years more targets and drugs may be discovered, but the approach will remain the same and this book will thus become, and for many years remain, the leading reference for ROSopathies and their treatment by network pharmacology. Chapter "Soluble Guanylate Cyclase Stimulators and Activators" is available open access under a Creative Commons Attribution 4.0 International License via link.springer.com.

ISBN: 9783030685102

Standard No.: 10.1007/978-3-030-68510-2doiSubjects--Topical Terms:

583819
Pharmacology.

LC Class. No.: RM1-950

Dewey Class. No.: 615

Reactive Oxygen Species = Network Pharmacology and Therapeutic Applications /
LDR:04010nam a22004095i 4500 001 1045917
003 DE-He213
005 20210924103905.0
007 cr nn 008mamaa
008 220103s2021 sz | s |||| 0|eng d
020 $a 9783030685102 $9 978-3-030-68510-2
024 7 $a 10.1007/978-3-030-68510-2 $2 doi
035 $a 978-3-030-68510-2
050 4 $a RM1-950
072 7 $a MMG $2 bicssc
072 7 $a MED071000 $2 bisacsh
072 7 $a MKG $2 thema
082 0 4 $a 615 $2 23
245 1 0 $a Reactive Oxygen Species $h [electronic resource] : $b Network Pharmacology and Therapeutic Applications / $c edited by Harald H. H. W. Schmidt, Pietro Ghezzi, Antonio Cuadrado.
250 $a 1st ed. 2021.
264 1 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2021.
300 $a VIII, 425 p. 70 illus. in color. $b online resource.
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
347 $a text file $b PDF $2 rda
490 1 $a Handbook of Experimental Pharmacology, $x 1865-0325 ; $v 264
505 0 $a Part I: ROS Revisited: Changing the Focus from Oxidative Stress and Redox Biology to Redox Medicine -- Demystifying oxidative stress -- Oxidants in Physiological Processes -- Network Medicine-Based Unbiased Disease Modules for Drug and Diagnostic Target Identification in ROSopathies -- Part II Targeting antioxidant responses -- Development of Telintra as an Inhibitor of Glutathione S-Transferase P -- Perspectives on the Clinical Development of NRF2-Targeting Drugs -- Part III: Inhibiting ROS formation and toxification -- NOX Inhibitors: From Bench to Naxibs to Bedside -- Nitric Oxide Synthase Inhibitors into the Clinic at Last -- Xanthine Oxidoreductase Inhibitors -- Monoamine Oxidase Inhibitors: From Classic to New Clinical Approaches -- Inhibition of Myeloperoxidase -- Part IV: Stimulating/substituting ROS -- Effects of Mammalian Thioredoxin Reductase Inhibitors -- Cardiovascular Therapeutic Potential of the Redox Siblings, Nitric Oxide (NO•) and Nitroxyl (HNO), in the Setting of Reactive Oxygen Species Dysregulation -- Tetrahydrobiopterin and Nitric Oxide Synthase Recouplers -- Part V: Repairing ROS damage -- Soluble Guanylate Cyclase Stimulators and Activators – Peter Sander -- Inhibitors of Advanced Glycation End Product (AGE) Formation and Accumulation.
520 $a Reactive oxygen species (ROS) have been implicated in almost every human disease phenotype, without much, if any, therapeutic consequence foremost exemplified by the failure of the so-called anti-oxidants. This book is a game changer for the field and many clinical areas such as cardiology and neurology. The term ‘oxidative stress’ is abandoned and replaced with a systems medicine and network pharmacology-based mechanistic approach to disease. The ROS-related drugs discussed here target either ROS- forming or ROS -modifying enzymes for which there is strong clinical evidence. In addition, ROS targets are included as they jointly participate in causal mechanisms of disease. This approach is transforming the ROS field and represents a breakthrough in redox medicine indicating a path to patient benefit. In the coming years more targets and drugs may be discovered, but the approach will remain the same and this book will thus become, and for many years remain, the leading reference for ROSopathies and their treatment by network pharmacology. Chapter "Soluble Guanylate Cyclase Stimulators and Activators" is available open access under a Creative Commons Attribution 4.0 International License via link.springer.com.
650 0 $a Pharmacology. $3 583819
650 0 $a Cardiology. $3 593957
650 0 $a Neurosciences. $3 593561
650 0 $a Medical biochemistry. $3 1254555
650 1 4 $a Pharmacology/Toxicology. $3 593882
650 2 4 $a Medical Biochemistry. $3 668897
700 1 $a Schmidt, Harald H. H. W. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 896318
700 1 $a Ghezzi, Pietro. $e editor. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1349382
700 1 $a Cuadrado, Antonio. $e editor. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1349383
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer Nature eBook
776 0 8 $i Printed edition: $z 9783030685096
776 0 8 $i Printed edition: $z 9783030685119
776 0 8 $i Printed edition: $z 9783030685126
830 0 $a Handbook of Experimental Pharmacology, $x 0171-2004 ; $v 224 $3 1254015
856 4 0 $u https://doi.org/10.1007/978-3-030-68510-2
912 $a ZDB-2-SBL
912 $a ZDB-2-SXB
950 $a Biomedical and Life Sciences (SpringerNature-11642)
950 $a Biomedical and Life Sciences (R0) (SpringerNature-43708)